Semaglutide
GLP-1 receptor agonist for weight management and metabolic health.
About Semaglutide
Semaglutide is an analog of glucagon-like peptide-1 (GLP-1) that works by mimicking the natural hormone that regulates appetite and satiety. Originally developed to treat type 2 diabetes, it has shown extraordinary results in body-weight management, with average losses of 15–20% of body weight in clinical trials. It acts on the brain to reduce appetite and on the digestive tract to slow gastric emptying.
How it works
- 1Mechanism: mimics the GLP-1 hormone, reducing appetite centrally and slowing gastric emptying.
- 2Typical protocol: weekly subcutaneous injection with gradual dose titration over the first 4–8 weeks.
- 3Expected timeline: reduced appetite from week 1; clinically meaningful weight loss between weeks 8 and 20.
- 4Follow-up: medical follow-up every two weeks for the first 2 months, then monthly.
Suggested protocol: Titration from a low starting dose up to a maintenance dose according to tolerance.
Benefits
- Significant, sustained weight loss (15–20%)
- Reduced appetite and cravings
- Improved insulin resistance
- Reduced cardiovascular risk
- Improved metabolic markers
- Glycemic control in type 2 diabetes
Safety and compliance
Protocol supervised by Dra. Marian Tufano
Professional license (cédula) 12353680, verifiable with SEP
- COFEPRIS-regulated clinic. Peptides prepared in licensed compounding pharmacies.
- Investigational / clinical use under medical prescription. Not FDA-approved as an over-the-counter treatment.
- Approved by the FDA and COFEPRIS for weight management
- Common side effects: mild nausea (transient in the first weeks)
- Requires gradual dose titration under medical supervision
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Pregnancy and breastfeeding
- Acute pancreatitis
Frequently asked questions about Semaglutide
Answers specific to this peptide. For questions about the program in general, visit our general FAQ.
Typical candidates have a BMI ≥ 27 with at least one comorbidity, or a BMI ≥ 30. The medical evaluation reviews your history, lab work and goals before prescribing.
Clinical trials show an average loss of 15–20% of body weight at 68 weeks. Your result will depend on adherence, nutrition and physical activity.
When you stop, some appetite returns. That is why we design a gradual exit protocol with nutrition and follow-up to maintain results.
We use semaglutide compounded in COFEPRIS-licensed compounding pharmacies. The active molecule is the same as in Ozempic/Wegovy.
Mild nausea, constipation or reflux during the first weeks. These usually resolve with dose adjustment and diet. Your physician guides you step by step.
Yes. In some protocols it is combined with body-composition peptides (CJC-1295/ipamorelin) to preserve muscle mass during weight loss.
Price
Ask at consultation
Personalized quote after medical evaluation
1 month
start
Ask at consultation
3 months
Ask at consultation
6 months
Ask at consultation
Administration
Weekly subcutaneous injection
Duration
Ongoing treatment per medical evaluation
Prior medical evaluation required.
Related peptides
Other protocols in the Weight Management category that are often combined with Semaglutide.
Take the Next Step
For Your Health Today
Schedule your complimentary medical evaluation and find out whether a molecular optimization program is right for you. At your pace, calm and clear.